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An understanding at the molecular level of the events involved in antigen-
specific T cell activation has been a primary but elusive goal of modern immu-
nology . The critical initial event involves T cell receptor-associative recognition
of appropriately processed antigen and a specific la molecule at the antigen-
presenting cell (APC)/T cell interface . However, direct demonstration of antigen
on the cell surface has not been straightforward (1-5) . If antigen were in fact
present on the presenting cell surface and bound to the la molecule or the
external surface of the cell membrane before binding to theT cell receptor, one
would expect it to be freely accessible to macromolecules in solution . Yet,
paradoxically, it has been notoriously difficult to blockantigen presentation using
antibodies specific for the antigen, in contrast to antibodies to the la molecule
(4-8) . Though a few cases of blocking with antipeptide antibodies have been
reported (9, 10), others have not been able to detect such blocking in similar
experiments (7, 8) . Even in the former two cases, it was not possible to determine
the mechanism and site of the blocking . Thus questions of antigen's existence
on the presenting cell surface have not been resolved by studies of antibody
blocking . Other recent studies using aldehyde-modified presenting cells suggest
that relevant antigen should be present in some form on the cell surface (11) but
provide no insight into its form or location .
We reasoned that many antibodies made to peptides in solution or to native
protein may not bind the conformation of the peptide when it is bound to the
presenting cells with sufficient affinity to block presentation . Therefore, in the
current study we use the high-affinity avidin-biotin interaction to demonstrate
cell surface inhibition of antigen presentation to T cells . Biotin was specifically
conjugated to a site on the peptide close to that recognized by the T cell but far
enough away to avoid interfering with activity for T cell stimulation . These
studies show that, under physiologic conditions, immunologically relevant anti-
gen is present on the presenting cell in a manner that is both freely accessible to
large macromolecules in solution and necessary for antigen-specific T cell acti-
vation . Interpreted in the context of structural information currently available
for participants in the ternary complex, these findings hold implications for
models of antigen presentation forT cell recognition .
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Materials and Methods
Mice.
￿
Mice used in these studies were 6- to 12-wk-old B10.D2 mice (The Jackson
Laboratories, Bar Harbor, ME) or B I O.GD bred by us from breeding stock kindly provided
by Dr. Donald Shreffler, St. Louis, MO .
T Cell Clones.
￿
T cell clones were derived from sperm whale myoglobin-specific T cells
from BIO .D2 mice and maintained as described previously (12). Clone 14.1 is specific for
the epitope centered around lysine 140 of myoglobin in association with I-Ed. This site
was originally identified and studied in bulk cell populations and subsequently in this and
other T cell clones using natural sequence-variant myoglobins, cleavage peptides, and
synthetic peptides (13-15). Clone 9.27 is specific for an epitope in the region of glutamic
acid 109 in association with I-Ad (12). Characterization of this site has similarly been
performed in bulk and cloned populations using variant myoglobins, fragments, and
synthetic peptides (13, 15, 16).
Antigens.
￿
Sperm whale myoglobin was prepared as described previously (12). Synthetic
peptide 132-146 ofsperm whale myoglobin was synthesized by manual solid-phase peptide
synthesis as described previously (14). The trifluoroacetic acid (TFA)'-protected lysine
derivative was selected for use in the synthesis to enable selective amino-terminal labeling
of the completed peptide (17). Thus, after cleavage of the peptide from the resin by
anhydrous hydrogen fluoride, the e-amino groups of lysines 133, 140, and 145 remained
blocked by the TFA group. We refer to this peptide as 132-146(TFA). Protein concen-
tration of 132-146(TFA) was estimated by the method of Bradford using a BSA standard
(18).
Preparation of N-a-biotinyl-132-146.
￿
^-500 nmol of 132-146(TFA) was biotinylated
using 12 .5 gmol (4.3 mg) of N-hydroxysuccinimide (NHS)-biotin (Pierce Chemical Co.,
Rockford, IL) and 12 .5 tamol (5 .5 mg) of sulfo-NHS-biotin (Pierce Chemical Co.) in 0.05
M borate buffer, pH 9, in 50% dimethyl formamide (DMF) for 16 h at room temperature
with stirring. The reaction mixture was then chromatographed on a Bio-Gel (Bio-Rad
Labbratories, Richmond, CA) P2 gel filtration column (1 .5 X 80 cm) in 50% DMF to
separate peptide from unreacted reagents. Discrete peaks were collected, lyophilized,
dissolved in 1 M piperidine, blanketed under nitrogen, and incubated at 4°C overnight
with stirring to remove TFA blocking groups. Samples were then lyophilized, redissolved
in 9% formic acid, and chromatographed on a Bio-Gel P4 gel filtration column X 90 cm).
The resulting fractions were qualitatively analyzed for the presence of biotin by spotting
on filter paper and developing with the ureido ring-specific reagent diethylaminocinna-
maldehyde (DACA) (19). Biotin-containing fractions were then assayed for specific anti-
genic activity in a T cell proliferation assay as described below.
HPLC Separation and Avidin Binding Analysis.
￿
Selected gel filtration peaks were further
characterized by reversed-phase HPLC using a Waters Associates (Milford, MA) system
and a SynChropak RP-P C18 column (SynChrom, Inc., Linden, IN) and a water, 0.1
TFA/acetonitrile, 0 .1 % TFA solvent system. Gradient elution at 1 ml/min was typically
used starting at 100% water/TFA and increasing acetonitrile/TFA by 0.66%/min. Elution
was monitored at 214 and 280 nm.
The presence or absence of biotin in resolved peaks was determined by specific
adsorption by avidin-agarose. The sample to be analyzed was mixed with avidin-agarose
(Sigma Chemical Co., St. Louis, MO) containing 20 nmol of biotin-binding capacity in a
total volume of 200 Al. After incubation for 30 min at room temperature with occasional
mixing, the avidin-agarose was sedimented by centrifugation in a table-top centrifuge.
The supernatant was filtered (0 .45 Am) and analyzed by HPLC as above. A parallel
incubation was performed containing 100 nm0I D-biotin (Sigma Chemical Co.), added
before addition of peptide as a control.
T Cell Proliferation Assay.
￿
Assays were performed using complete medium consisting
of RPM1 1640 with 44% Eagle-Hanks' amino acid medium, 10% FCS, 5 X 10-5 M 2-ME,
2 mM fresh-frozen L-glutamine (Gibco, Grand Island, NY), 100 U/ml penicillin, and 100
wg/ml streptomycin (Gibco) as described previously (12). APC were prepared from spleens
'Abbreviations used in this paper:
￿
DMF, dimethyl formamide; NHS, N-hydroxysuccinimide; TFA,
trifluoroacetic acid.1442
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of unimmunized mice by mashing, unit gravity sedimentation of debris, hypotonic lysis of
red cells, washing, and irradiation with 3,300 rads from a "7Cs source. The standard T
cell proliferation assay was performed by coculturing 4 X 105 APC with 104 T cells in the
presence or absence of antigen and/or avidin in 96-well plates with 0.2 ml total volume
per well . After 72 h, wells were pulsed with 1'Ci of [3Hlthymidine (New England Nuclear,
Boston, MA) and harvested 16 h later onto glass fiber disks using a semiautomated device
(Skatron, Sterling, VA). The radioactivity on each disc was determined by liquid scintil-
lation counting using a Beckman LS2800 scintillation counter (Beckman Instruments,
Inc., Palo Alto, CA). Assays were performed in triplicate and the geometric means and
standard errors of the means were determined. Variations of this standard protocol were
employed as outlined in the figure legends.
Results
Preparation of N-a-biotinyl-132-146.
￿
After biotinylation of synthetic peptide
132-146(TFA), chromatography on Bio-Gel P2 yielded three discrete peaks
designated 1, II, and 111 . This step was performed to separate peptide from
unreacted biotinylating reagent before deblocking of the e-amino groups of
lysines 133, 140, and 145 so as to avoid biotinylation at these sites. After
deblocking, chromatography of I, 11, and III on Bio-Gel P4 yielded several
incompletely resolved peaks in each case numbered with Arabic numerals ac-
cording to elution time. Qualitative analysis for biotin was positive for peaks 1 .1,
1 .2, 1.3, 11.6, and 11 .7 . HPLC analysis of peak 1 .1 yielded three peaks with
retention times of 39.5, 47 .5, and 52 .6 min with relative areas of 1 .52, 2 .15, and
1 .00, respectively . Total specific adsorption of peaks 47.5 and 52 .6 by avidin-
agarose was observed, indicating that all of the molecules in these peaks contained
biotinyl groups.
Activity of N-a-biotinyl-132-146.
￿
The gel filtration chromatographic fractions
containing biotin were tested for specific T cell antigenic activity for clone 14 .1 .
As shown in Fig. 1, activity was predominantly found in peak 1 .1 with lesser
activity in peak 1 .2 and none in peaks 1.3, 11 .6, and 11.7. Peak 1.1 had no
stimulatory activity for clone 9 .27 possessing an irrelevant specificity (data not
shown) . The HPLC resolved peaks from 1.1 were tested with clone 14.1, and
only peak 52 .6 was active. Thus, a single HPLC peak from 1.1 was active and
biotinylated. Peak I .1 material was titered for specific antigenic activity for clone
14.1, and the lowest concentration giving maximal proliferation was used in
subsequent functional studies. This material possessed the expected structural
and functional properties of N-a-biotinyl-132-146, and will be referred to as
B132.
Avidin Inhibits Presentation of B132.
￿
Proliferation of T cell clone 14.1 was
assayed with APC and antigen (myoglobin, 132-146, or B132) added 90 min
before T cells with or without the addition of avidin (5 aM final concentration)
90 min before, concurrent with, or 90 min after the addition of T cells (Fig. 2)
to examine the effectiveness of avidin addition at different times relative to T
cell addition . Marked (90%) inhibition of the response to B132 was observed
with avidin added 90 min before T cells, but only slight inhibition ofthe response
to myoglobin and 132-146 was seen. The kinetics of inhibition appeared to be
rapid relative to the rate of T cell activation, because concurrent addition gave
60% inhibition, and addition after 90 min of culture with T cells still yielded
50% inhibition . A standard 60-min interval between avidin addition and T cellCEASE ET AL .
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FIGURE 1 .
￿
Antigenic activity of chromatographic peaks of biotinylated peptide . After gel
filtration chromatography, peaks (numbered as in Materials and Methods) were assayed for
their ability to stimulate clone 14 .1 in the standard T cell proliferation assay as described
under Materials and Methods . T cell ['H]thymidine incorporation is shown expressed as the
background subtracted geometric mean cpm (Ocpm) with the error bars indicating the range
for SEM for triplicate wells . The no-antigen background was 310 cpm.
addition was adopted for subsequent experiments . The effectiveness of avidin
addition at varying times relative to antigen B132 is explored in the pulse/chase
experiments described below .
Avidin Specifically Inhibits Presentation by APC Prepulsed with B132 .
￿
Inhibition
of presentation in the standard T cell proliferation assay could occur at sites of
antigen uptake, intracellular trafficking, or presentation to the T cell . To rule
out the possibility of inhibition occurring before or during antigen uptake or
association with the APC, we used antigen pretreatment or pulsing. As shown in
Fig . 3, presentation ofB132 to clone 14 .1 by prepulsed APC was clearly inhibited
by avidin at a dose that had no effect on the presentation of the myoglobin
control . The 5 gM avidin dose was found to be optimal for obtaining specific
inhibition, without the nonspecific inhibition seen at 5- to 25-fold higher concen-
trations . In addition, this study demonstrates that full inhibition is seen even
when avidin is added at a time when free antigen has been removed and any
uptake of antigen by the APC that is going to occur is already complete . Thus,
avidin blocking is not merely blocking of uptake by the cell .
Avidin Inhibits Presentation by Pulsed and Chased APC .
￿
Pulsing intervals of up
to 8 h were examined and found to show specifically inhibitable antigen presen-
tation, though the maximal proliferation seen with B132 tended to be lower
than that seen in the standard (nonpulsed) assay protocol . Presentation of peptide
132-146 to these T cell clones has been shown not to require proteolytic
processing (20) . To exclude the possibility that the avidin inhibition of B132
presentation was occurring before or during some other critical processing step,1444
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Avidin inhibition of presentation of biotinylated peptide. The ability of avidin to
specifically inhibit presentation of the biotinylated peptide was studied in the standard T cell
proliferation assay and the effect of time of addition of avidin relative to T cells was also
examined. In the control groups (no antigen, myoglobin, peptide 132-146), avidin wasadded
90 min before clone 14.1 T cells. In the group testing the biotinylated peptide B132, avidin
addition was either 90 min before, concurrent with, or 90 min after addition of T cells. The
inset diagram summarizes protocol timing. T cell [sH]thymidine incorporation is shown
expressed as the background subtracted geometric mean cpm (Acpm) with the error bars
indicating the range for SEM for triplicate wells. The no-antigen background was 1,588 cpm.
['HITHYMIDINE INCORPORATION (ACPM x 10')
ANTIGEN AVIDIN (MM) 0 2 4
￿
6 8 10 12 14 16 18 20 22 24 26 28 30
Myoglobin 0
5
25
125
B132
￿
0
5
25
125
Antigen
￿
Wash T Cells
Avidin
FIGURE 3.
￿
Simple pulsing protocol and titration of avidin for inhibition of presentation of
B132. APC (5 x 106cells/ml)were pulsed with antigen for4 hat 37°C with occasional mixing.
Cellswere then irradiated, washed three times, andplated in 96-well plates at 4 x 105cells/well
in 0.1 ml. Varyingdoses of avidin were added in 0.05 ml followed by 10' clone 14 .1 T cells
in 0.05 ml I h later. The final concentrations of avidin are shown for each group. The inset
diagram summarizes protocol timing. T cell [5H]thymidine incorporation is shown expressed
as the background subtracted geometric mean cpm (Acpm) with the error bars indicating the
range for SEM for triplicate wells. The no-antigen background was 206 cpm.
experiments were performed with a chase interval of up to 16 h between the
end of an 8-h pulse period and the addition of avidin and T cells. Fig. 4 shows
the specific inhibition seen in such an experiment with 8 h of pulsing, followed
by washing and 8 h of chase. Specific inhibition is also clearly seen with 8 h ofANTIGEN AVIDIN 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
T>-1
B132
FIGURE 4.
￿
Avidin inhibits presentation ofbiotin peptide even after a culture interval (chase)
between pulsing and addition of avidin and T cells. APC were pulsed as described in the
legend to Fig. 4except that a pulsing period of 8hwas used, followed by irradiation, washing,
and plating. A further 8-h culture interval at 37°C was allowed before addition of avidin to
allow possible intracellular trafficking of antigen to be completed, followed by addition of
clone 14 .1 T cells I h later. The inset diagram summarizes protocol timing. T cell [5H]
thymidine incorporation is shown expressed as the background subtracted geometric mean
cpm (Acpm) with the error bars indicating the range for SEM for triplicate wells. The no-
antigen background was 225 cpm.
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FIGURE 5.
￿
Increasing APC density does not diminish avidin inhibition. APCwere pulsed as
described in the legend to Fig. 4 except that a pulsing period of 8 h was used, followed by
irradiation, washing, and plating at 2 X 105, 4 X 10, or 6 X 105 cells/well. A 16-h chase
culture interval wasallowedbefore addition of avidin followed by T cells I h later. The inset
diagram summarizes protocol timing. T cell [5H]thymidine incorporation is shown expressed
as the background subtracted geometric mean cpm (Acpm) with the error bars indicating the
range for SEM for triplicate wells. The no-antigen backgrounds were 406, 558, and 653 cpm
for 2 X 105, 4 X 105, and 6 X 105 APC/well, respectively.
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pulsing and 16 h of chase (Fig. 5). Therefore, avidin inhibition can occur after
all intracellular trafficking that may be necessary is completed, so that inhibition
cannot be attributed to blocking or altering this trafficking. The magnitude of
the T cell response to B132 tended to be lower after the chase interval but still
demonstrated highly significant responses with stimulation indices of 10-50-fold
over the low backgrounds of a few hundred counts per minute obtained with
the T cell clone. It was postulated that this might be due to a lower affinity of
B132 for structures associated with the APC and consequent dissociation of some1446
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Avidin
TABLE I
Antigen Mixing Study
Antigen
APCs were pulsed with peptide 132-146 (2 juM) or the combination of
132-146 and B132 for 8 h, irradiated, washed, andplated. After a I6-h
culture interval (chase), avidin was added to the final concentrations
shown, followed 1 h later by T cells. The 4-d T cell [3Hjthymidine
incorporation is shown for each group expressed as the background
subtracted geometric mean cpm (Acpm) with the SE factor for triplicate
wells shown in parentheses. Theno-antigen background was 557 cpm.
antigen during this period. If this were the case, increasing numbers of APC
might provide additional peptide antigen-binding sites and thereby partially
compensate for the lower B132 affinity and increase the T cell proliferative
response. As shown in Fig. 5, this appeared to be the case. The interpretation
that there is a greater amount of immunologically relevant antigen with increas-
ing APC number in the B132 cultures is further supported by the finding that
the response remains almost totally inhibitable. The possibility that B132-pulsed
cells were more sensitive to nonspecific avidin toxicity is excluded in Table I.
Including this concentration of B132 mixed with 132-146 in a pulse/chase
experiment did not result in inhibition by avidin.
Avidin Inhibition Is Not Dependent on Intracellular Trafficking of Antigen.
￿
As
an alternative means of determining whether intracellular trafficking of antigen
was required for effective inhibition by avidin, APC pulsing was performed in
the presence of monensin (Fig. 6). Monensin has been shown, at this dose, to
inhibit endocytic and secretory activities of cells and recycling of receptors, class
I and II MHC antigens, and surface immunoglobulin (21-26; B. Pernis, personal
communication). The control response to native myoglobin was appropriately
abrogated by the monensin treatment, as had been demonstrated previously
(20). This control indicated that trafficking necessary for processing was effec-
tively inhibited. However, addition of monensin to APC 30 min before and
during 2 h of antigen pulsing had no effect on the T cell response to the peptide
antigen B132, an indication that monensin was not toxic and that biotin-peptide
did not need such processing. Under these conditions, in which intracellular
trafficking was blocked by monensin, avidin still completely and specifically
blocked the response to B132. Thus, avidin inhibition is not dependent on
intracellular trafficking or reexpression of internal antigen and therefore must
occur at some other site. The pulsing, pulse/chase, and monensin experiments
together strongly suggest that blocking by avidin is occurring at the cell surface.
Antigens on APC Do Not Dissociate and Reassociate to Reform Immunologically
132-146 132-146 + B132
PM otpm
0 39,693 37,338
(1.05) (1 .14)
20 57,118 53,669
(1 .05) (1 .12)
40 46,670 43,359
(1 .02) (1 .14)CEASE ET AL .
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FIGURE 6.
￿
Monensin inhibition of intracellular trafficking does not affect avidin inhibition
ofantigen presentation . APCwere incubated with or without 30 ;1M monensin 30 min before
andduring 2 hof antigen pulsing . Cells were then irradiated, washed three times, and plated
as describedabove . Avidin additions were made, followed by clone 14 .1 T cells 1 h later. The
inset diagram summarizes protocol timing. T cell ['H]thymidine incorporation is shown
expressed as the background subtracted geometric mean cpm (Ocpm) with the error bars
indicating the range for SEM for triplicate wells . The no-antigen backgrounds were 840 and
457 cpm in the absenceand presence of monensin, respectively.
Relevant Antigen .
￿
If antigen were constantly dissociating and reassociating with
the APC, one might postulate that avidin could block presentation by binding to
dissociated B132 before it could reassociate with the APC. We reasoned that
antigen dissociating into the solution phase may reassociate with the original cell
or a different cell and thus, if an antigen-pulsed cell were cocultured with a
nonpulsed cell, eventually an equilibrium would be reached with equal amounts
of antigen on both cells . Thus, to test this dissociation/association hypothesis, we
pulsed B10.GD APC with myoglobin, 132-146, or B132 and cocultured them
with nonpulsedB10.D2 APC in aT cell proliferation assay with clone 14.1 . The
B10.GD cells do not express an I-Ed molecule and, thus, the only way that
activation of the I-Ed-restricted clone could occur would be if antigen were to
dissociate from the B10.GD cells and reassociate with the B10.D2 cells in a
manner that forms immunologically relevent antigen . As is shown in Table 11,
proliferation was not observed . Thus, such dissociation and reassociation was not
detectable . Therefore, avidin blocking is not due to inhibition of such hypothet-
ical reassociation .
Discussion
The presence of immunologically relevant antigen on the cell surface of the
APC has been central to most models of antigen presentation to T cells (27-29) .
The initial inability to block presentation with antigen-specific antibodies
prompted alternative models that allowed for concealment of antigen with
exposure induced only through interaction with the T cell (4, 30) . Though1448 AVIDIN INHIBITION OF BIOTIN-PEPTIDE PRESENTATION
TABLE 11
Antigen Dissociation/association Study: Coculture ofAntigen-pulsed and
-nonpulsed I-Ed-positive or -negative APC in T Cell Proliferation Assay
(1 .28) (1 .18) (1 .17) (1 .06)
T cell-depleted B10.D2 andB10.GD cellswere pulsed with antigens or medium
(nonpulsed) for 2 h, followed by irradiation, washing three times, and plating 2
X 105 pulsed with 2 X 105 nonpulsed APC in the standard T cell proliferation
assay. T cell ['Hlthymidine incorporation is shown for each group expressed as
the geometric mean cpm (cpm) with the SE factor for triplicate wells shown in
parentheses.
blocking T cell recognition of surface-haptenated APC by antibodies could be
demonstrated, effective blocking of presentation of exogenous soluble antigen
has only been demonstrated more recently and has been successful in only a few
(9, 10, 31) of several well-designed attempts (4-8) to date.
The studies of Lamb et al . (9) show marked inhibition usingantipeptide rabbit
serum and peptide-specific T cell clones. Inhibition was not seen in an uncloned
line. Corradin et al. (10), using monoclonal antipeptide antibodies, were able to
demonstrate inhibition for both T cell clones and T cell lines. Though the
pulsing experiments in these two studies effectively rule out blocking of antigen
uptake by the APC as the mechanism of inhibition, potential blocking at other
sites was not explored. In neither case was there a chase period between antigen
pulse and antibody addition. Malek and Shevach (32) have shown that, immedi-
ately after pulsing, a significant intracellular antigen pool is present, whereas by
24 h after washing, almost all cell-associated antigen is associated with the cell
surface. Consequently, a brief exposure to blocking antibody after antigen
pulsing, as employed by Lamb et al. (9) would be expected to result in durable
blocking only if antibody were taken up by the APC and were eventually able to
block presentation of the intracellular antigen pool either intracellularly or
extracellularly. In the pulse experiment of Corradin et al. (10), one could
postulateeither ongoingsurfaceblocking by antibody or antibody uptake leading
to intracellular blocking.
Surface blocking was suggested in the study of Shevach et al. (31), though in
a somewhat indirect manner. Their approach was to pulse cells with exogenous
antigen, allow a minimum period for antigen processing, modify the cell surface
with TNP, and assay for the ability ofanti-TNP antibodies to inhibitpresentation
to T cells. They observed inhibition in cases where the antigen contained lysine
groups with E-amino groups available for TNP modification but not when lysine-
free antigens were used.
Pulsed
APC
Nonpulsed None
Antigen
Myoglobin 132-146 B132
cpm
D2 D2 222 8,605 96,411 14,564
(1 .05) (1 .43) (1.18) (1 .29)
D2 GD 371 8,171 66,265 13,839
(1 .23) (1 .12) (1 .03) (1 .17)
GD D2 371 205 195 284
(1 .23) (1 .27) (1 .04) (1 .48)
GD GD 243 229 220 419CEASE ET AL.
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Other studies, however, have failed to detect blocking of presentation by
antibodies to the antigen, including antibodies to the antigenic peptide (4-8).
Therefore, the conflicting results using antibodies have not allowed a resolution
of the question of antigen on the cell surface. We reasoned that perhaps the
antibodies made to peptides in solution generally have insufficient affinity for
the conformation assumed by the peptide on the presenting cell . In the present
study we attempted to develop an experimental system that would avoid many
of the difficulties of previous approaches and would allow a clear molecular
interpretation of results. An antigen probe was constructed by site-specific
biotinylation of a peptide with well-characterized structure/activity properties
for antigen-specific activation of a T cell clone (14). This enabled high-affinity
binding of avidin to the antigen regardless of its conformation and thereby
avoided potential problems of concealed determinants and low affinity possible
with antibodies. Specific inhibition ofantigen presentation by avidin wasobserved
in the standard T cell proliferation assay as well as under conditions designed to
require cell surface inhibition .
A simple pulse protocol using 8 h of antigen pulsing was used to rule out the
possibility that blocking of antigen uptake was the mechanism of inhibition. The
possibility that the mechanism of inhibition was through intracellular blocking
was addressed by two types of studies, providing in one case for completion of
intracellular antigen trafficking, and in the other case for ablation of such
trafficking. Careful studies of antigen processing have shown that immunologi-
cally relevant antigen becomes available to the T cell receptor after a minimum
processing period of ^-1 h (32). The reexpression of internalized antigen appears
to be relatively complete by 24 h (32). Thus, after 24 h of pulse/chase, strong
specific blocking of presentation by avidin would require cell surface or extra-
cellular blocking. Clear blocking was seen in such experiments. The alternative
approach was to use the carboxylic ionophore monensin to interfere with intra-
cellular traffic in the APC. Previous studies in this laboratory have shown that
monensin abrogates the presentation of native myoglobin, while presentation of
peptide 132-146 is unaffected (20). These results are confirmed in the controls
in Fig. 6. Formally identical results have been found in other antigen systems
(11, 33). The ability of monensin to inhibit both endocyticand secretory activities
of cells has been demonstrated in a variety of experimental systems and supports
its use to inhibit intracellular trafficking and reexpression in studies of antigen
presentation (21-23). Particularly relevant is the observation that monensin
abolishes recycling of class I and II MHC antigens and surface immunoglobulin
(24-26 ; B. Pernis, personal communication) . In the current study, specifically
inhibitable stimulation by B132 was seen after antigen pulsing in the presence of
monensin. This indicates that intracellular trafficking andreexpression of antigen
was not necessary for inhibition and thus that the critical blocking event could
not be intracellular. We were unable to obtain reproducible antigen presentation
to untransformed T cell clones by glutaraldehyde-fixed APC. Thus, we did not
employ this additional approach in these studies. Taken together, the pulse/chase
and monensin studies provide strong independent evidence that the blocking is
not intracellular.
Because blocking appeared notto be occurring before uptake or intracellularly,1450
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we proposed two remaining potential sites of blocking, in extracellular solution
during transient dissociation, or at the cell surface. If the flux of antigen off of
and back onto APC were great enough, one could imagine that avidin blocks
presentation by binding to solution-phase antigen and preventing reassociation.
To determine the magnitude of antigen dissociation and reassociation, we
antigen-pulsed BIO.GD APC, which do not express an I-Ed molecule and hence
cannot present antigen to clone 14.1, and cocultured these cells with nonpulsed
MOM APC in a T cell proliferation assay with clone 14.1 . No antigen presen-
tation was seen. Therefore, the amount of antigen dissociating from the BIO.GD
cells and associating with the B10.D2 cells to form immunologically relevant
antigen was insignificant and, thus, avidin inhibition by binding to dissociated
antigen was improbable. Thus, we conclude that the blocking event is occurring
at the site of immunologically relevant antigen on the APC cell surface, and that
such antigen is present on the surface in a form accessible to a molecule the size
of avidin.
There are three possible sites for antigen on the cell surface consistent with
ultimate coordinate recognition of antigen and Ia by the T cell receptor. Watts
et al. (34) and Walden et al . (35) have shown that a lipid membrane, the
appropriate Ia molecule, and antigen are sufficient elements for generating a
functional receptor stimulation complex for the T cell. Thus, (a) antigen could
be directly associated with some part of the Ia forming the stimulation complex
for subsequent binding; (b) antigen could be stably bound to both Ia and the
lipid membrane at theirjunction to form the stimulation complex; or (c) antigen
could be free in the lipid membrane in equilibrium with a low-affinity transient
complex with Ia, which may be stabilized by T cell receptor binding. The third
model provides for a large reservoir of antigenic peptide that could be dynami-
cally sampled by the Ia and/or the T cell receptor. In fact, one may speculate
that one reason for the immunodominance of amphipathic peptides (36) may be
a positive selection based on the ability to associate stably with the cell membrane.
A large pool of antigen at a high local concentration in the membrane may be
necessary to provide a sufficient number of antigen-la complexes, given the
relatively low affinity of peptide binding to Ia (37). Indeed, Watts et al. (38) have
recently presented data from fluorescence energy transfer studies showing that
the presence of the T cell receptor significantly increases the amount of antigen
associated with Ia, possibly by stabilizing a weak complex of antigen and Ia. On
the other hand, experiments using antigen-pulsed and glutaraldehyde-fixed
presenting cells suggest that there are a significant number of crosslinkable
antigen-Ia complexes before interaction with the T cell receptor (11). This
concentration of complexes should, if in true equilibrium, depend on the total
concentration of peptide in the membrane . Thus, we conclude that blocking is
occurring at the APC cell surface, probably either at the site of the stimulation
complex for the T cell receptor or by preventing a membrane-associated pool of
peptide from associating with Ia.
While the features of this model are consistent with the antibody-blocking
studies mentioned previously, several experimental considerations limited the
structural conclusions that could be drawn directly from those studies alone. Cell
surface blocking appeared to be clearly shown only in the study of Shevach et al .CEASE ET AL.
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(31); however, in that study the cells themselves were conjugated with TNP, and
thus it was impossible to completely control for the effect of having TNP on
other cell surface molecules. Localization ofantibody-binding regions onantigen
was not precisely known in any of the previous studies. Even in the study of
Shevach et al. (31), although the defined hapten TNP was used, the sites of
specific lysine modifications and their proximity to critical antigenic residues
could not be known. The 35-A-diameter Fab' portion of antibody (39) should
have more access to recessed sites such as the la-lipid membrane junction as
compared with the 55 x 55-A binding face ofavidin (40). However, the overall
rotational sphere of an intact antibody molecule is much larger than that of
avidin, and thus antibody can potentially sterically block moieties more remote
from their binding site than can avidin . Though Fab' fragments in principle
could minimize this latter concern, the affinity of univalent Fab' binding com-
pared with bivalent binding has not permitted their successful use in studies of
antibody blocking of presentation (31). The lower affinity of univalent binding
of whole antibody to relatively dispersed antigen on the APC cell surface has
been proposed as the reason for failure to see blocking in several optimized
experimental systems (7, 31). Use ofthe biotin-avidin system with its Kd of 10-'5
M (41) appears to overcome effectively such affinity limitations.
Thus, our data suggest that immunologically relevant antigen is at the cell
surface, freely accessible to macromolecules the size ofavidin.
Summary
Although studies ofthe association ofantigen with APC have been complicated
by antigen-processing requirements, recent studies have suggested that immu-
nologically relevant antigen should be present on the APC surface. Nevertheless,
blocking of antigen presentation with antibody to the antigen has not been
demonstrable in most systems. To study this problem we developed a system
using avidin to block presentation ofamino-terminal biotinylated synthetic pep-
tide 132-146 ofsperm whale myoglobin (B132) to a murine T cell clone specific
for this site in association with I-Ed. >95% specific inhibition was observed with
doses of B132 equipotent to unmodified peptide. Specific blocking could be
observed: (a) after pulsing APC with antigen, washing, and incubating for a
chase period of 8-16 h before addition ofavidin and T cells to assure adequate
time for intracellular trafficking and maximal display of antigen on the cell
surface, or (b) when monensin is present during the antigen pulse to inhibit such
traffic. Therefore, the inhibition appeared to be occurring at the cell surface
unless dissociation and reassociation were constantly occurring. To distinguish
these, BIO.GD APC (I-Ed-negative) were pulsed with antigen and cocultured
with B10.D2 APC (I-Ed-positive). No detectable antigen presentation resulted.
Thus, minimal dissociation and reassociation between antigen and APC occurs
and, consequently, blocking by extracellular solution-phase binding of avidin to
antigen is unlikely. Taken together, these data suggest that the blocking is
occurring at the cell surface. Thus, under physiologic conditions, immunologi-
cally relevant antigen necessary for T cell activation appears to be present on
the APC surface and is freely accessible to macromolecules the size of avidin.1452
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These findings hold specific implications for models of antigen presentation for
T cell recognition .
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